Black Diamond Therapeutics Inc. has reported financial results for the first quarter ending March 31, 2025, along with a corporate update. The company posted a net income of $56.5 million for the first quarter of 2025, a significant turnaround from a net loss of $18.2 million during the same period in 2024. General and administrative expenses decreased to $5.0 million from $6.7 million in the previous year, attributed to a restructuring initiative announced in October 2024. Research and development expenses also saw a decline, amounting to $10.5 million compared to $13.5 million in 2024, due to improved workforce efficiencies and a strategic focus on the development of BDTX-1535. Black Diamond ended the first quarter of 2025 with $152.4 million in cash, cash equivalents, and investments, up from $98.6 million as of December 31, 2024. The company also highlighted a net cash inflow from operations, with $53.4 million provided in the first quarter of 2025, contrasting with a $21.2 million cash outflow during the same period the previous year. Significant developments include the ongoing Phase 2 trial enrollment for BDTX-1535, targeting newly diagnosed patients with non-classical epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). Black Diamond plans to release initial clinical data for this trial in the fourth quarter of 2025 and seek FDA feedback for a potential pivotal registrational path. Additionally, the recent global licensing agreement with Servier for BDTX-4933 has bolstered the company's cash position, extending its financial runway into the fourth quarter of 2027. Black Diamond is poised to commence pivotal development of BDTX-1535 in the first half of 2026, pending FDA feedback.